Objective: To determine annual incidence, etiology, severity, and short-and long-term mortality of first-time, nonanoxic status epilepticus (SE) in adults in a population-based retrospective cohort study.
| INTRODUCTION
Status epilepticus (SE) is the second most important neurological emergency, with an estimated annual incidence between 8 and 41/100 000 inhabitants. 1, 2 It is associated with significant mortality and risk for marked neurological deficiency. 3 Reported 30-day mortality rates range from 7% to 30%, 4 and risk factors for in-hospital death after SE have been extensively studied. However, little is known about the long-term outcome of SE and most studies on SE epidemiology are based on register data or data from health insurance. Legriel et al observed a 90-day mortality of 18.8%; 38.8% had marked functional impairment. 5 A cohort study by Logroscino et al (studying both children and patients with and without anoxia) found that 40% of patients who survived the first 30 days after SE died within the next 10 years. The mortality rate was threefold that of the general population. 6 A recent study from Finland found a 1-year mortality after refractory SE of 25.4%, which was substantially higher than in-hospital mortality of 7.4%. 7 Given that SE is a symptom of various different diseases, the crucial factors causing mortality after discharge are unknown.
We therefore performed a population-based study including all adult SE patients on the island of Funen. Funen is considered representative for Western countries and often used for population-based studies. 8, 9 The purposes of the study were (1) to determine annual incidence etiology and severity of first-episode nonanoxic SE in the adult population and (2) to determine short and long-term mortality of patients with first-episode SE. In an additional exploratory analysis, we aimed at establishing putative risk factors associated with long-term mortality.
| MATERIALS AND METHODS

| Cohort
The island of Funen is the third largest island in Denmark, with around 384 000 adult inhabitants in 2014. Odense University Hospital has the only neurological/neurophysiological department on the island and serves all acute neurological patients. To identify all patients with SE in the year 2014, we prospectively identified all adult patients referred to the Department of Neurophysiology for acute electroencephalography (EEG) irrespective of the suspected diagnosis and identified additional patients with suspected SE based on International Classification of Diseases, 10th revision (ICD-10) codes at discharge and clinical information (STROBE 10 compliant flow chart: Figure 1 ). Patients not treated for SE at the Odense University Hospital (eg, patients treated in nursing homes) could not be included. Patients' charts were analyzed retrospectively. SE was defined clinically as ongoing clinical seizure lasting >5 minutes or repetitive seizures without normalization of consciousness in between as defined in Brophy et al. 11 Nonconvulsive SE in coma was diagnosed using the Salzburg criteria. 12 Patients with SE due to postanoxic etiologies, children (<18 years old), patients not living on the island of Funen, and patients with a previous episode of SE were excluded. Refractory patients were defined as patients with no response to first-line treatment with benzodiazapines and second-line treatment with phenytoin, phenobarbital, valproate, or levetiracetam. Narcosis was defined as treatment with continuous infusions with propofol and/or midazolam typically until burst suppression in EEG. For age and gender adjustment, we used gender-specific mortality rates for the general Danish population in the years 2013-2017 that was provided by Statistics Denmark (www.dst.dk, accessed April 4, 2018). 13 For confirmation of our results, we used a cohort of patients treated for SE between 2008 and 2013 at the Odense University Hospital. Definition of SE and inclusion/exclusion criteria were identical to the 2014 cohort. Patients were identified retrospectively based on ICD-10 codes at discharge, and patients' charts were analyzed retrospectively. Survival and clinical data were available for all patients. Permission to handle patient records was acquired from the Danish Data Protection Agency (file 13/ 42567) and the Danish Health Authority (file 3-3013-696/ 1/).
| Status Epilepticus Severity Score
We determined the Status Epilepticus Severity Score (STESS) based on the electronic patient records from admission.
14 STESS relies on four outcome predictors:
extent of consciousness impairment (alert or somnolent/ confused = 0, stuporous or comatose = 1), worst seizure type (simple focal, complex focal, absence, and myoclonic seizures = 0, generalized convulsive = 1, nonconvulsive
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| Etiology and semiology
Etiology was defined as the proceeding factor that was assumed to cause SE by the treating neurologists based on the information available in electronic patient records. For analysis, etiology of SE was classified according to International League Against Epilepsy recommendations 15 into acute symptomatic (stroke, intoxication, encephalitis), remote symptomatic (posttraumatic, postencephalitic, poststroke, etc), progressive central nervous system disorders (brain tumor, dementias, etc), SE in defined electroclinical syndromes, and unknown/unprovoked seizure.
| Outcome measures
The degree of disability at discharge was retrospectively determined using the modified Rankin Scale (mRS) at discharge. It ranges from 0 to 6 points, from no symptoms (0) to death (6) . Mortality at the end of study (October 17, 2017) was determined by date of death in Danish Civil Registration System, available from electronic patient records.
| Statistics
Statistical analysis was made using SPSS 24.0 (IBM) and R (v3.5). Statistical significance of prognostic factors was determined with Pearson chi-square test or Fisher's exact test in a multifactor analysis. Logistic regression (method: Enter) was used for multivariate analysis. Significance was set at P < 0.05. Long-term outcome was analyzed using the Kaplan-Meier curve; log-rank test was used to determine statistical significance.
| RESULTS
| Patient cohort
Of 430 patients referred to acute EEG and 86 patients with clinical suspicion of SE, 67 adults living on Funen were diagnosed with SE. Thirty-eight adult patients fulfilled the Salzburg criteria for nonconvulsive SE in coma; 29 were diagnosed based on clinical criteria (incidence in the year 2014: 17.4/100 000 adult inhabitants). Fourteen of 67 patients suffered from SE secondary to cerebral anoxia after cardiorespiratory arrest. An additional 12 patients had a previous episode of SE ( Figure 1 ). A total of 41 adult patients were diagnosed with first-time, nonanoxic SE, resulting in an incidence of 10.7/100 000 adult inhabitants. Median STESS was 3; 90.2% of the patients had STESS between 2 and 5. Table 1 gives an overview over the patient cohort.
| In-hospital mortality
Ten of 41 patients (24.4%) with SE died before discharge. SE was successfully treated in 87.8% of all patients. Four of five patients with SE refractory to all treatment died in hospital ( Figure 2A ). Six patients died due to underlying etiology or because of complications (sepsis, multiorgan failure). None of our patients suffered from bilateral tonicclonic seizures that could not be controlled with antiepileptic treatment. All patients with SE refractory to all treatment suffered from EEG-verified nonconvulsive SE in coma. At discharge, 19.5% were severely disabled (mRS = 3-5), 39.0% were discharged with minor disability (mRS = 1-2), and 17.1% had no symptoms (mRS = 0). In a multifactor analysis of known prognostic factors, STESS and its components were associated with in-hospital mortality (Table 2 ).
| Long-term outcome
Long-term mortality with a minimum follow-up of 2.5 years after SE was 53.7%. Twenty-two of 41 patients had died at end of study; survival stabilized after 2 years ( Figure 2B ). In an exploratory analysis (n = 27 patients), we excluded all patients with SE due to progressive disease (n = 3) and SE due to acute symptomatic causes (n = 11). Nonetheless, mortality did not substantially improve and was 46.7%. To confirm the results, we analyzed a second cohort of SE patients from 2008-2013 with identical inclusion and exclusion criteria (n = 88 patients, demographics in Table S1 ). In this second cohort with a follow-up of up to 8 years, we confirmed stabilization of survival after 2-3 years and a substantially higher mortality 2 years after discharge as compared to in-hospital mortality ( Figure 2B ).
| Prognostic factors associated with longterm outcome
In an exploratory analysis aiming at the identification of putative prognostic factors associated with long-term outcome, we combined both cohorts to achieve sufficient statistical power and analyzed the subgroup of patients who could be discharged alive from the hospital (n = 108). In a multivariate analysis including putative prognostic factors associated with long-term outcome after discharge, clinical status at discharge was significantly associated with survival after discharge in both cohorts (Table 3 ; Figure 2C and 2D). Eighty percent of patients who died during follow-up had an mRS of 2 or worse at discharge. STESS (and its components), narcosis, treatment length, and etiology were not associated with long-term outcome ( Table 3) . As expected, gender and age correlated with long-term mortality. 
| DISCUSSION
In contrast to acute mortality of SE, only a few studies have focused on long-term outcome. In our cohorts, the overall mortality of SE increased after discharge and the mortality after discharge was substantially higher than inhospital mortality. The mortality after 2-3 years was >50% in adults with newly diagnosed, nonanoxic SE. Even after correction for potentially fatal diseases like brain tumors, the overall mortality hardly decreased. Although our data do not allow final conclusions on the causes of high longterm mortality, the data suggest that SE and not only etiology may be crucial. The major strength of our study was the 100% followup of all patients due to the linkage of the Danish Civil Registration System and the electronic medical record. This allowed the precise assessment of long-term mortality without any dropouts. However, this study also has limitations. The sample size of the cohort was relatively low. Although we screened 341 adult patients, only 41 fulfilled all inclusion and exclusion criteria. The low number of patients certainly limits final conclusions on the exact long-term mortality and associated risk factors, and reproduction of our data in other cohorts is required to substantiate our findings. Given that we prospectively identified putative patients, the retrospective design of the study appears less problematic, at least for the 2014 cohort. In this cohort, there is no substantial risk of bias because all patients with minimal risk of SE are referred to the EEG department and our population is therefore very similar to a population assessed in a prospective study from Switzerland. 16 The mortality in our cohort is on the higher end of what was otherwise reported but not higher than in other cohorts. 3 The slightly higher mortality at discharge could be due to the high proportion of elderly subjects in our study sample (65.8%), which is strongly associated with in-hospital mortality and likely explains why the overall survival never plateaus ( Figure 2B ). Furthermore, our study also had a high incidence of nonconvulsive SE in coma (12.2%), which is also known for high mortality rates. 17, 18 The retrospective design, however, is a limitation of the 2008-2013 cohort. Both cohorts had identical inclusion/ T A B L E 3 Multivariate analysis (logistic regression) of risk factors associated with death after discharge (patients discharged alive from 2008 to 2014)
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Dead at end of study Alive at end of study P Gender, n (%) (Table 3) . Conversely, the positive association of mRS with survival after discharge was found in both cohorts and is likely of substantial importance. Our interpretation of this finding is that neurological damage due to SE is the major cause for mortality after discharge. However, more evidence in support of this hypothesis is required and the study was not powered to robustly exclude other important variables not considered (eg, length of narcosis, duration of seizures 20 ) . From a clinical point of view, the lack of association of narcosis with long-term mortality is almost as important, given that narcosis is associated with a substantial morbidity in the acute phase. 20, 21 Although patients treated with narcosis are certainly more severely affected by SE, their long-term outcome does not differ. We interpret our data as a call for more aggressive treatment of patients who are at risk of neurological damage secondary to SE. Despite the relatively low number of patients, we found all established associations with in-hospital mortality, suggesting that the cohort was representative. Furthermore, we found a similar incidence of SE as compared to other studies (eg, Switzerland 8.0/100 000 1 ; Bologna, Italy 13.1/ 100 000 22 ). A higher incidence was found in Germany (15.8/100 000). 23 The minor variability in reported population incidences may be explained by differences and variation in population composition, inclusion and exclusion criteria (eg, postanoxic encephalopathies), different age range and gender composition, and inclusion of first-time episode of SE only. Underascertainment is likely not a flaw of this study, given the high number of acute EEG screened for this study. A number of SE patients with long-lasting epilepsy treated with diazepam in the nursing home are not referred to the hospital and could therefore not be included in this study. However, inclusion of these patients would have hardly improved the mortality. 23 In summary, we feel that all these aspects do not affect the overall message that SE patients do have a bad long-term prognosis that is even worse than the outcome for patients requiring treatment for acute stroke. 24 The finding that survival stabilizes after 2 years suggests that future studies should use 2-year overall survival as an endpoint to avoid underestimation of mortality. In summary, we conclude that mortality of SE in the first 2 years after diagnosis is substantially higher than inhospital mortality and reaches >50%. mRS at discharge is a significant predictor for long-term mortality.
